Pancreatic cancer serum biomarker PC-594: Diagnostic performance and comparison to CA19-9.
about
Future of the Renal Biopsy: Time to Change the Conventional Modality Using Nanotechnology.Metabolomic biomarkers of pancreatic cancer: a meta-analysis study.Differentiation of benign and malignant solid pancreatic masses using magnetic resonance elastography with spin-echo echo planar imaging and three-dimensional inversion reconstruction: a prospective study.Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis.The Use of Biomarkers in Early Diagnostics of Pancreatic Cancer
P2860
Pancreatic cancer serum biomarker PC-594: Diagnostic performance and comparison to CA19-9.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Pancreatic cancer serum biomar ...... ance and comparison to CA19-9.
@ast
Pancreatic cancer serum biomar ...... ance and comparison to CA19-9.
@en
type
label
Pancreatic cancer serum biomar ...... ance and comparison to CA19-9.
@ast
Pancreatic cancer serum biomar ...... ance and comparison to CA19-9.
@en
prefLabel
Pancreatic cancer serum biomar ...... ance and comparison to CA19-9.
@ast
Pancreatic cancer serum biomar ...... ance and comparison to CA19-9.
@en
P2093
P2860
P356
P1476
Pancreatic cancer serum biomar ...... ance and comparison to CA19-9.
@en
P2093
Asuka Mochizuki
Bassirou Chitou
Dayan B Goodenowe
Dushmanthi Jayasinghe
Qingan Zheng
Shawn A Ritchie
P2860
P304
P356
10.3748/WJG.V21.I21.6604
P407
P577
2015-06-01T00:00:00Z